Autobahn Gets $32.7M for Depression Treatment
BIOTECH: Funding to Support Drug Trials
■ By GEORGE LURIE
San Diegobased Autobahn Therapeutics raised $32.7 million in a funding round announced last week (Sept. 8). Proceeds from the round will be used to advance Phase 1 and Phase 2 clinical trials of the biotech’s lead drug candidate – ABX-002.
Read latest San Diego Business Journal online.